Fox Run Management L.L.C. Buys Shares of 5,611 Biohaven Ltd. (NYSE:BHVN)

Fox Run Management L.L.C. purchased a new position in Biohaven Ltd. (NYSE:BHVN) in the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund purchased 5,611 shares of the company’s stock, valued at approximately $210,000.

Several other institutional investors and hedge funds have also made changes to their positions in BHVN. KLP Kapitalforvaltning AS acquired a new position in Biohaven in the 4th quarter valued at about $601,000. Sei Investments Co. grew its holdings in shares of Biohaven by 55.7% during the fourth quarter. Sei Investments Co. now owns 69,082 shares of the company’s stock worth $2,580,000 after buying an additional 24,723 shares in the last quarter. American Century Companies Inc. grew its holdings in shares of Biohaven by 9.5% during the fourth quarter. American Century Companies Inc. now owns 558,761 shares of the company’s stock worth $20,870,000 after buying an additional 48,286 shares in the last quarter. Quantbot Technologies LP acquired a new position in shares of Biohaven in the fourth quarter valued at approximately $355,000. Finally, DCF Advisers LLC lifted its stake in shares of Biohaven by 16.1% during the fourth quarter. DCF Advisers LLC now owns 36,000 shares of the company’s stock valued at $1,345,000 after buying an additional 5,000 shares during the period. 88.78% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

Several analysts have commented on BHVN shares. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Biohaven in a research note on Tuesday, December 17th. Royal Bank of Canada reaffirmed an “outperform” rating and issued a $61.00 price objective on shares of Biohaven in a research report on Tuesday, March 4th. Morgan Stanley reduced their target price on Biohaven from $69.00 to $63.00 and set an “overweight” rating on the stock in a research report on Friday, March 7th. JPMorgan Chase & Co. lowered their price target on Biohaven from $72.00 to $68.00 and set an “overweight” rating for the company in a report on Wednesday, March 5th. Finally, Deutsche Bank Aktiengesellschaft set a $60.00 price objective on shares of Biohaven and gave the stock a “buy” rating in a report on Thursday, March 20th. Fourteen research analysts have rated the stock with a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat.com, Biohaven has a consensus rating of “Buy” and a consensus price target of $62.77.

Insiders Place Their Bets

In other news, Director John W. Childs acquired 32,700 shares of the company’s stock in a transaction dated Tuesday, March 4th. The shares were bought at an average price of $30.47 per share, for a total transaction of $996,369.00. Following the completion of the purchase, the director now directly owns 2,320,571 shares of the company’s stock, valued at approximately $70,707,798.37. This trade represents a 1.43 % increase in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. 16.00% of the stock is currently owned by insiders.

Biohaven Stock Down 2.8 %

Shares of BHVN stock opened at $27.59 on Friday. Biohaven Ltd. has a fifty-two week low of $26.57 and a fifty-two week high of $55.72. The firm’s 50 day moving average price is $35.15 and its two-hundred day moving average price is $41.32. The stock has a market cap of $2.82 billion, a price-to-earnings ratio of -2.95 and a beta of 1.27.

Biohaven (NYSE:BHVN) last posted its earnings results on Monday, March 3rd. The company reported ($1.85) earnings per share for the quarter, missing the consensus estimate of ($1.56) by ($0.29). On average, equities analysts forecast that Biohaven Ltd. will post -8.9 EPS for the current fiscal year.

About Biohaven

Biohaven Ltd., together with its subsidiaries, focuses on discovering, developing, and commercializing therapies for immunology, neuroscience, and oncology worldwide. The company's pipeline products include Troriluzole, which is in Phase 3 clinical trial for the treatment of neurological and neuropsychiatric illnesses; BHV-5500 that blocks glutamate signaling mediated by post-synaptic NMDA receptors; Taldefgrobep Alfa, which is in Phase 3 clinical trial for the treatment of spinal muscular atrophy and obesity; BHV-7000, a candidate in Phase 2/3 clinical trials for the treatment of focal and generalized epilepsy, bipolar disorder, and major depressive disorder; BHV-2100 that is in Phase 1 clinical trials for the treatment of migraines and neuropathic pain; and BHV-8000, a product candidate in Phase 1 clinical trials for the treatment of early Alzheimer's and Parkinson's disease, sclerosis, and amyloid-related imaging abnormalities.